Current development and introduction of hemoglobin-based blood substitutes



Cite item

Full Text

Abstract

Substantial efforts to develop a blood substitutes on the base of modified hemoglobin have been made since the end of last century. The review reflects main achievements and complications on the way of development of hemoglobin-based oxygen carriers.

Full Text

Restricted Access

About the authors

E A Selivanov

Russian Research Institute for Hematology and Transfusiology of Health Ministry of Russian Federation, St. Petersburg

N N Pshenkina

Research Institute for Experimental Medicine of the Northwest Branch of Russian Academy of Medical Sciences, St. Petersburg

Email: p5hcnkina@mail.ru

E V Murzina

S.M. Kirov Military Medical Academy, St. Petersburg

G A Sofronov

Research Institute for Experimental Medicine of the Northwest Branch of Russian Academy of Medical Sciences, St. Petersburg

M D Khanevich

Russian Research Institute for Hematology and Transfusiology of Health Ministry of Russian Federation, St. Petersburg

V A Sarychev

Gelenpol, Ltd., Obninsk, Kaluga region

References

  1. Воробьев С.И. Перфторуглеродные эмульсии I и II поколения // Хим.-фарм. журн. 2009. Т. 43. № 4. С. 30^10.
  2. Голубев А.М., Белоярцев Ф.Ф., Васильев А.Э., Покровский Ю.Э. Реакции биологических систем при замещении крови эмульсиями фторуглеродов. М.: ТЕМС, 1993.
  3. Дьяконов А.Н., Бурданов А.П., Корик В.Е., Коновалов С.В. Применение геленпола при операциях на толстой кишке // Применение инфузионных антиги- поксантов и искусственных переносчиков кислорода в хирургии: Сб. науч. тр. СПб., 1999. С. 16-18.
  4. Иваницкий Г.Р. Биофизика на пороге нового тысячелетия: перфторуглеродныс среды и газотранспортные кровезаменители // Биофизика. 2001. Т. 46. №1. С. 5-33.
  5. Корик В.Е. Применение кровезаменителя-перенос- чика кислорода на основе модифицированного гемоглобина при лечении больных с тяжелой кровопотерей: автореф. дис.. канд. мед. наук. СПб., 2000.
  6. Кузнецова Н.П., Гудкин Л.Р., Мишаева Р.Н. Способ получения полигемоглобина с повышенной кислородтранспортной эффективностью / Патент RU 2132687, 1999.
  7. Кузнецова Н.П., Гудкин Л.Р., Селиванов Е.А. и др. Кровезаменитель-переносчик кислорода, состав для его получения и способ получения полимерного модифицированного гемоглобина / Патент RU 2162707, 2001.
  8. Самсонов Г.В. и др. Солевой раствор полимерного гемоглобина / Патент SU 183354A3, 1992.
  9. Селиванов Е.А., Быстрова И.М., Ханевич М.Д., Парашин М.Е. Экспериментальное и клиническое изучение кровезаменителя-переносчика кислорода на основе модифицированного гемоглобина // Физиологически активные вещества на основе перфторуглеродов в военной медицине: Сб. матер, науч. конф. СПб., 1997. С. 95-96.
  10. Селиванов Е.А., Софронов Г. А., Ханевич М.Д. и др. Эффективность применения перфторана в хирургической практике // Трансфузиология. 2008. № 2. С. 78-88.
  11. Селиванов Е.А., Софронов Г.А., Ханевич М.Д., Скрябин О.Н. Возможности применения модифицированного гемоглобина в хирургии // Трансфузиология. 2008. Т. 9. № 2. С. 68-77.
  12. Склифас А.Н., Шехтман Д.Г., Образцов В.В. и др. Механизмы распределения и выведения перфторуглеродов при многократных введениях // Биофизика. 1998. Т. 43. № 1.С. 171-176.
  13. Софронов Г.А., Селиванов Е.А., Ханевич М.Д. Переносчики кислорода: состояние проблемы и перспективы развития // Применение инфузионных антигипоксантов и искусственных переносчиков кислорода в хирургии: Сб. науч. тр. СПб., 1999. С. 75-85.
  14. Сухоруков В.П., Рагимов А.А., Пушкин С.Ю. и др. Перфторан - перфторуглеродный кровезаменитель с газотранспортной функцией: пособие для врачей. 2-е изд., перераб. и доп. М., 2008.
  15. Филатов Ф.П. Вирусная безопасность переливания крови // Природа. 2005. № 3. URL: http://vivovoco. rsl.ru/VV/JOURNAL/NATURE/03 05/VIRUS.HTM
  16. Ханевич М.Д., Софронов Г.А., Селиванов Е.А., Корик В.Е. Применение искусственного переносчика кислорода на основе модифицированного гемоглобина у больных с гастродуоденальными кровотечениями // Вести, хирургии им. И.И. Грекова. 2000. Т. 159. №6. С. 51-54.
  17. Шевченко Ю.Л., Шабалин В.Н., Зарнвчацкий М.Ф., Селиванов Е.А. Руководство по общей и клинической трансфузиологии. СПб.: Фолиант, 2003.
  18. Ярочкин В.С., Кочемасов В.В. Гемодилюция. Настоящее и будущее. М., 1997.
  19. Alayash АЛ. Redox and Radical Reactions of Hemoglobin Solutions: Toxicities and Protective Strategies // Blood Substitutes / Ed. by R. Winslow. San Diego: Academic Press, 2006. P. 197-205.
  20. Amberson W.R. Blood substitutes // Biol. Rev. 1937. Vol. 12. P. 48-85.
  21. Benesch R.E., Benesch R., Rcnthal R.D., Maeda N. Affinity labeling of the polyphosphate binding site of hemoglobin // Biochemistry. 1972. ѴЫ. 11. № 19. P. 3576-3582.
  22. Bjorkholm M., Fagrell B., Przybelski R. et al. A phase I single blind clinical trial of a new oxygen transport agent (MP4), human Hb modified with maleimide-ac- tivated polyethylene glycol // Haematologica. 2005. Vol. 90. № 4. P. 505-515.
  23. Blood substitutes / Ed. by R. Winslow. San Diego: Academic Press, 2006.
  24. Carmichael F.J., АН A.C., Campbell J.A. et al. A phase I study of oxidized raffinose cross-linked human hemoglobin // Crit. Care Med. 2000. Vol. 28. № 7. P. 2283- 2292.
  25. Carson J.L., Noveck H., Berlin J.A., Gould S.A. Mortality and morbidity' in patients with very low postoperative Hb levels who decline blood transfusion // Transfusion. 2002. Vol. 42. № 7. P. 812-818.
  26. Chang T.M. A nanobiotechnologic therapeutic that transport oxygen and remove oxygen radicals: for stroke, hemorrhagic shock and related conditions // Artificial cells: biotechnology, nanomedicine, regenerative medicine, blood substitutes, bioencapsulation and cell/stem cell therapy / Ed. by T.M. Chang. Singapore: World Science Publisher, 2007. P. 62-92.
  27. Chang T.M. Nanobiotechnology for Hemoglobin-based blood substitutes // Crit. Care Clin. 2009. Vol. 25. № 2. P. 373-382.
  28. Cheng D.C. Safety and efficacy of o-raffinose cross- linked human hemoglobin (Hemolink) in cardiac surgery // Can. J. Anaesth. 2001. Vol. 48. № 4 (Suppl.) S. 41^18.
  29. Cohn C.S., Cushing M.M. Oxygen therapeutics: per- fluorocarbons and blood substitute safety // Crit. Care Clin. 2009. Vol. 25. № 2. P. 399-414.
  30. D’Agnillo F., Chang T.M. Polyhemoglobin-superoxide dismutase-catalase as a blood substitute with antioxidant properties //Nat. Biotechnol. 1998. Vol. 16. № 7. P.667-671.
  31. Drobin D., Kjellstrom B.T., Malm E. et al. Hemodynamic response and oxygen transport in pigs resuscitated with maleimide-polyethylene glycol-modified hemoglobin (MP4) // J. Appl. Physiol. 2004. ѴЫ. 96. № 5. P. 1843-1853.
  32. Epstein J.S., Holmberg J.A. Progress in monitoring blood safety // Transfusion. 2010. Vol. 50. № 7. P. 1408-1412.
  33. Gould S.A., Moore E.E., Hoyt D.B. et al. The first randomized trial of human polymerized hemoglobin as a blood substitute in acute trauma and emergent surgery //J. Am. Coll. Surg. 1998. Vol. 187. №2. P. 113-120.
  34. Gould S.A., Moore E.E., Hoyt D.B. et al. The life-sustaining capacity of human polymerized hemoglobin when red cells might be unavailable // J. Am. Coll. Surg. 2002. Vol. 195. № 4. P. 445^452.
  35. Gould S.A., Moore E.E., Moore F.A. et al. Clinical utility of human polymerized hemoglobin as a blood substitute after acute trauma and urgent surgery // J. Trauma. 1997. Vol. 43. № 2. P. 325-331.
  36. Greenburg A.G., Kim H.W. Use of an oxygen therapeutic as an adjunct to intraoperative autologous donation to reduce transfusion requirements in patients undergoing coronary artery bypass graft surgery // J. Am. Coll. Surg. 2004. Vol. 198. № 3. P. 373-385.
  37. Henkel-Honke T., Oleck M. Artificial oxygen carriers: a current review // AANA. 2007. Vol. 75. № 3. P. 205- 211.
  38. Hill S.E., Gottschalk L.I., Grichnik K. Safety and preliminary efficacy of hemoglobin raffimer for patients undergoing coronary artery bypass surgery // J. Cardio- thorac. Vase. Anesth. 2002. Vol. 16. № 6. P. 695-702.
  39. Hoffman S.J., Looker D.L., Roehrich J.M. et al. Expression of fully functional tetrameric human hemoglobin in Escherichia coli // Proc. Natl. Acad. Sci. USA. 1990. Vol. 87. № 21. P. 8521-8525.
  40. Izumi Y., Sakai H., Kose T. et al. Evaluation of the capabilities of a hemoglobin vesicle as an artificial oxygen carrier in a rat exchange transfusion model // ASAIO. 1997. Vol. 43. № 4. P. 289-297.
  41. Jahr J.S., Varma N. PolyHeme. Northfield Laboratories // IDrugs. 2004. Vol. 7. № 5. P. 478-482.
  42. Jahr J.S., Weeks D.L., Desai P. et al. Does OxyVita, a new-generation hemoglobin based oxygen carrier, or Oxyglobin acutely interfere with coagulation compared with normal saline or 6% hetastarch? II J. Cardiotho- rac. Vas. Anesth. 2008. Vol. 22. № 1. P. 34-38.
  43. Jia Y., Alayash A.l. Effects of cross-linking and zero- link polymerization on oxygen transport and redox chemistry of bovine hemoglobin // Biochim. Biophys. Acta. 2009. Vol. 1794. № 8. P. 1234-1242.
  44. Kasper S.M., Walter M., Grime F. et al. Effects of a hemoglobin-based oxygen carrier (HBOC-201) on hemodynamics and oxygen transport in patients undergoing preoperative hemodilution for elective abdominal aortic surgery //Anesth. Analg. 1996. Vol. 83. № 5. P. 921-927.
  45. Kerger H., Tsai A.G., Saltzman D.J. et al. Fluid resuscitation with 02 vs. non-02 carriers after 2 h of hemorrhagic shock in conscious hamsters //Am. J. Physiol. 1997. Vol. 272. №> 1 (Pt. 2). H525-537.
  46. Kemer T., Aiders O., Veit S. et al. DCL-Hb for trauma patients with severe hemorrhagic shock: the European “On-Scene” multicenter study // Intensive Care Med. 2003. Vol. 29. № 3. P. 378-385.
  47. Kim H.W., Greenburg A.G. Artificial oxygen carriers as red blood cell substitutes: a selected review and current status // Artif. Organs. 2004. Vol. 28. № 9. P. 813- 828.
  48. Kim H.W, Greenburg A.G. Toward 21st century blood component replacement therapeutics: artificial oxygen carriers, platelet substitutes, recombinant clotting factors, and others // Artif. Cells Blood Substit. Immobil. Biotechnol. 2006. Vol. 34. № 6. P. 537-550.
  49. LaMuraglia G.M., O’Hara P.J., Baker W.H. et al. The reduction of the allogenic transfusion requirement in aortic surgery with a hemoglobin-based solution // J. Vase. Surg. 2000. Vol. 31. № 2. P. 299-308.
  50. Lamy M.L., Daily E.K., Brichant J.F. et al. Randomized trial of diaspirin cross-linked hemoglobin solution as an alternative to blood transfusion after cardiac surgery//Anesthesiology. 2000. Vol. 92. № 3. P. 646- 656.
  51. Levy J.H., Goodnough L.T., Greilich P.E. et al. Polymerized bovine hemoglobin solution as a replacement for allogeneic red blood cell transfusion after cardiac surgery: results of a randomized, double-blind trial // J. Thorac. Cardiovasc. Surg. 2002. ѴЫ. 124. № 1. P. 35- 42.
  52. Loeb A.L., McIntosh L.J., Raj N.R., Longnecker D.E. Resuscitation after hemorrhage using recombinant human hemoglobin (rHbl.l) in rats: effects on nitric oxide and prostanoid systems // Crit. Care Med. 1998. Vol. 26. №6. P. 1071-1080.
  53. Looker D., Abbott-Brown D., Cozart P. et al. A human recombinant haemoglobin designed for use as a blood substitute // Nature. 1992. Vol. 356. № 6366. P. 258- 260.
  54. Lowe K.C. Genomics and blood substitutes for 21st century Europe (“EuroBloodSubstitutes”) //Artif. Cells Blood Substit. Immobil. Biotechnol. 2006. Vol. 34. N 6. P. 589-599.
  55. Lowenstein C.J., Dinerman J.L., Snyder S.H. Nitric oxide: a physiologic messenger//Ann. Intern. Med. 1994. Vol. 120. № 3. P. 227-237.
  56. Malhotra A.K., Kelly M.E., Miller P.R. et al. Resuscitation with a novel hemoglobin-based oxygen carrier in a Swine model of uncontrolled perioperative hemorrhage // J. Trauma. 2003. Vol. 54. № 5. P. 915-924.
  57. Moncada S., Palmer R.M.J., Higgs E.A. Nitric oxide: physiology, pathophysiology and pharmacology // Pharmacol. Rev. 1991. Vol. 43. № 2. P. 109-142.
  58. Moore E.E., Moore F.A., Fabian T.C. et al. Human polymerized hemoglobin for the treatment of hemorrhagic shock when blood is unavailable: the USA multicenter trial // J. Am. Coll. Surg. 2009. Vol. 208. № 1. P. 1-13.
  59. Moskowitz D.M., McCullough J.N., Shander A. et al. The impact of blood conservation on outcomes in cardiac surgery: is it safe and effective? // Ann. Thorac. Surg. 2010. Vol. 90. № 2. P. 451-458.
  60. Murphy G.J., Reeves B.C., Rogers C.A. et al. Increased mortality, postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery // Circulation. 2007. Vol. 116. № 22. P. 2544- 2552.
  61. Nakaki T. Physiological and clinical significance of nitric oxide // Keio J. Med. 1994. Vol. 43. № 1. P. 15-26.
  62. Natanson C., Kern S.J., Lurie P. et al. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis // JAMA. 2008. Vol. 299. № 19. P.2304-2312.
  63. Ness P.M., Cushing M.M. Oxygen therapeutics. Pursuit of an alternative to the donor red blood cell //Arch. Pathol. Lab. Med. 2007. Vol. 131. JNe 5. P. 734-741.
  64. Ning J., Wong L.T., Christoff B. et al. Haemodynamic response following a 10% topload infusion of Hemolink™ in conscious, anaesthetized and treated spontaneously hypertensive rats // Transfus. Med. 2000. Vol. 10. № l.P 13-22.
  65. Olofsson C., Ahl T., Johansson T. et al. A multicenter clinical study of the safety and activity of maleimide- polyethylene glycol Hemoglobin (Hemospan) in patients undergoing major orthopedic surgery //Anesthesiology. 2006. Vol. 105. № 6. P 1153-1163.
  66. Pearce L.B., Gawryl M.S., Rentko V.T. et al. HBOC- 201 (Hemoglobin GIutamer-250 (Bovine), Hemo- pure®): Clinical studies // Blood substitutes / Ed. by R. Winslow. San Diego: Academic press, 2006. P. 437-450.
  67. Pirie E., Green J. A framework to support safe blood transfusion practice // Nurs. Stand. 2010. Vol. 24. № 48. P. 35-40.
  68. Powanda D.D., Chang T.M. Cross-linked polyhemo- globin-superdioxide dismutase-catalase supplies oxygen without causing blood-brain barrier disruption or brain edema in a rat model of transient global brain ischemia-reperfusion // Art. Cells Blood Subsstit. Im- mobil. Biotechnol. 2002. Vol. 30. № 1. P. 25-42.
  69. Riess J.G. Oxygen carriers (“blood substitutes”) - raison d’etre, chemistry and some physiology // Chem. Rev. 2001. Vol. 101. Na 9. P. 2797-2920.
  70. Saezler R.K., Arfors K.E., Tuma R.F. et al. Polynitrox- ylated hemoglobin-based oxygen carrier: inhibition of free radical induced microcirculatory dysfunction // Free Radic. Biol. Med. 1999. Vol. 27. № 1-2. P. 1-6.
  71. Sakai H., Horinouchi H., Yamamoto M. et al. Acute 40 percent exchange-transfusion with hemoglobin-vesicles (HbV) suspended in recombinant human serum albumin solution: Degradation of HbV and erythropoi- esis in a rat spleen for 2 weeks // Transfusion. 2006. Vol. 46. № 3. P. 339-347.
  72. Sakai H., Masada Y., Horinouchi H. et al. Hemoglobin-vesicles suspended in recombinant human serum albumin for resuscitation from hemorrhagic shock in anesthetized rats // Crit. Care Med. 2004. Vol. 32. № 2. P. 539-545.
  73. Sakai H., Sou K., Horinouchi H. et al. Hemoglobin- vesicles as artificial oxygen carriers: present situation and future visions // J. Intern. Med. 2008. Vol. 263. № l.P. 4-15.
  74. Sakai H., Sou K., Horinouchi H. et al. Review of hemoglobin-vesicles as artificial oxygen carriers // Artif. Organs. 2009. Vol. 33. № 2. P. 139-145.
  75. Sakai H., Sou K., Tsuchida E. Hemoglobin-vesicles as an artificial oxygen carrier//Methods Enzymol. 2009. Vol. 465. P. 363-384.
  76. Sakai H., Takeoka S., Park S.I. et al. Surface modification of hemoglobin vesicles with poly(ethylene glycol) and effects on aggregation, viscosity, and blood flow during 90% exchange transfusion in anesthetized rats // Bioconjug. Chem. 1997. ѴЫ. 8. № 1. P. 23-30.
  77. Sakai H., Tomiyama K., Sou K. et al. Polyethylene glycol)-conjugation and deoxygenation enable longterm preservation of hemoglobin-vesicles as oxygen carriers in a liquid state // Bioconjug. Chem. 2000. Vol. 11. N9 3. P.425-432.
  78. Savitsky J.P., Doczi J., Black J., Arnold J.D. Clinical safety trial of stroma-free hemoglobin // Clin. Pharmacol. Ther. 1978. Vol. 23. № 1. P 73-80.
  79. Schubert A., Przybelski R.J., Eidt J.F. et al. Diaspirin- crosslinked hemoglobin reduces blood transfusion in noncardiac surgery: a multicenter, randomized, controlled, double-blinded trial // Anesth. Analg. 2003. Vol. 97. № 2. P. 323-332.
  80. Selivanov E.A., Kochetygov N.L., Bistrova I.M. et al. Study of polymerized hemoglobin in experiment // Artif. Cells Blood Substit. Immobil. Biotechnol. 1994. Vol. 22. № 5. P. 156.
  81. Siegel J.H., Fabian M., Smith J.A., Costantino D. Use of recombinant hemoglobin solution in reversing lethal hemorrhagic hypovolemic oxygen debt shock // J. Trauma. 1997. Vol. 42. № 2. P. 199-212.
  82. Simoni J. Artificial oxygen carriers: scientific and biotechnological points of view //Artif. Organs. 2009. Vol. 33. № 2. P. 92-96.
  83. Simoni J. Endothelial cell response to hemoglobin based oxygen carriers. Is the attenuation of pathological reactions possible? // Artificial Oxygen Carrier. Its Front Line / Kobayashi K., Tsuchida E., Horinouchi H. eds. Tokyo: Springer-Verlag, 2005. P. 25-75.
  84. Simoni J., Simoni G., Moeller J.F. Intrinsic toxicity of hemoglobin: how to counteract it // Artif. Organs. 2009. Vol. 33. № 2. P 100-109.
  85. Simoni J., Villanueva-Meyer J., Simoni G. et al. Control of oxidative reactions of hemoglobin in the design of blood substitutes: role of the ascorbate-glutathione antioxidant system //Artif. Organs. 2009. Vol. 33. №2. P. 115-126.
  86. Sloan Е.Р., Koenigsberg М., Gens D. et al. Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial // JAMA. 1999. ѴЫ. 282. № 19. P. 1857-1864.
  87. Sou K., Klipper R., Goins B. et al. Circulation kinetics and organ distribution of Hb vesicles developed as a red blood cell substitute // J. Pharmacol. Exp. Ther. 2005. Vol. 312. P.702-709.
  88. Spahn D.R., Kocian R. Artificial 0, carriers: status in 2005 // Curr. Pharm. Des. 2005. Vol. 11. № 31. P.4099-4114.
  89. Sprung J., Kindscher J.D., Wahr J.A. et al. The use of bovine hemoglobin glutamer-250 (Hemopure) in surgical patients: Results of a multicenter, randomized single-blind study //Anesth. Analg. 2002. Vol. 94. № 4. P. 799-808.
  90. Stowell C.P., Levin J., Spiess B.D., Winslow R.M. Progress in the development of RBC substitutes // Transfusion. 2001. Vol. 41. № 2. P. 287-299.
  91. Strauss R.G. Blood banking issues pertaining to neonatal red blood cell transfusions // Transfus. Sci. 1999. Vol. 21. № 1. P.7-19.
  92. Tsai A.G., Vandegriff K.D., Intaglietta M., Winslow R.M. Targeted O, delivery by low-PJ0 hemoglobin: a new basis for O, therapeutics //Am. j. Physiol. 2003. Vol. 285. № 4. P. 1411-1419.
  93. Vamvakas E.C., Taswell H.F. Epidemiology of blood transfusion // Transfusion. 1994. Vol. 34. № 6. P. 464- 470.
  94. Vandegriff K., Winslow R.M. Hemospan: design principles for a new class of oxygen therapeutic // Artif. Organs. 2009. Vol. 33. № 2. P. 133-138.
  95. Vandegriff K.D., Malavalli A., Wooldridge J. et al. MP4, a new nonvasoactive PEG-Hb conjugate // Transfusion. 2003. Vol. 43. №4. P. 509-516.
  96. von Dobschuetz E., Hutter J., Hoffmann T., Messmer K. Recombinant human hemoglobin with reduced nitric oxide-scavenging capacity restores effectively pancreatic microcirculatory disorders in hemorrhagic shock //Anesthesiology. 2004. Vol. 100. № 6. P. 1484-1490.
  97. Winslow R. Current status of blood substitute research: towards a new paradigm // J. Intern. Med. 2003. Vol. 253. № 5. P. 508-517.
  98. Winslow R.M., Chapman K.W., Vandegriff K.D., Young M. Hemospan® (MP4), A human hemoglobin modified with maleimide-polyethylene glycol // Blood Substitutes / Ed. by R. Winslow. San Diego: Academic Press, 2006. P. 470-482.
  99. Winslow R.M., Lohman J., Malavalli A., Vandegriff K.D. Comparison of PEG-modified albumin and hemoglobin in extreme hemodilution in the rat // J. Appl. Physiol. 2004. Vol. 97. № 4. P. 1527-1534.
  100. WongN., Chang T.M. Polyhemoglobin-fibrinogen: a novel oxygen carrier with platelet-like properties in a hemodiluted setting //Art. Cells Blood Substit. Im- mobil. Biotechnol. 2007. Vol. 35. № 5. P. 481-489.
  101. Yazer M.H., Triulzi D.J. Receipt of older RBCs does not predispose D-negative recipients to anti- D alloimmunization //Am. J. Clin. Pathol. 2010. Vol. 134. №3. P.443-447.
  102. Young M.A., Lohman J., Malavalli A. et al. Hemospan improves outcome in a model of peri-operative hemodilution and blood loss in the rat: comparison with hydroxyethyl starch // J. Cardiothorac. Vase. Anesth. 2009. Vol. 23. № 3. P. 339-347.
  103. Young M.A., Riddez L., Kjellstrom B.T. et al. MalPEG-hemoglobin (MP4) improves hemodynamics, acid-base status, and survival after uncontrolled hemorrhage in anesthetized swine // Crit. Care Med. 2005. Vol. 33. № 8. P. 1794-1804.
  104. Zhu X., Chu W., Wang F. et al. Variations in dominant antigen determinants of glutaraldehyde polymerized human, bovine and porcine hemoglobin // Art. Cells Blood Substit. Immobil. Biotechnol. 2007. Vol. 35. № 5. P. 518-532.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Selivanov E.A., Pshenkina N.N., Murzina E.V., Sofronov G.A., Khanevich M.D., Sarychev V.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74760 от 29.12.2018 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies